LAUSR

Objectives: Prostate cancer is the third most common cancer worldwide. The incidence is rising in the middle east. There is paucity of data about the clinicopathological features and outcomes of metastatic prostate cancer (mPCa) from the middle-east. We report the outcomes of mPCa from Oman.Methods: Consecutive men diagnosed with mPCa and treated at the university hospital in Oman between January 2006 and December 2017 were included in this study. Information about demographics, clinical, laboratory, pathological and radiological features at presentation, treatment, and survival outcomes was collected. Data were gathered until April 2019 or until patient’s death for progression-free survival (PFS) and overall survival (OS), whichever came first. Survival rates were estimated using the method of Kaplan and Meier. Univariate and multivariate analysis and Cox regression analyses were performed to study factors affecting the PFS and the OS. Results: Out of the 239 men diagnosed with PC over the study period, 62 were diagnosed with mPCa. The median age was 71 (range 57 – 92) years. Majority of patients (61.3%) had a Gleason score ≥8. Median PSA level was 100. Bone was the most common site of metastatic disease (90.3%). Majority of patients with hormone-sensitive disease were treated with testosterone suppression only, while abiraterone, enzalutamide and docetaxel were added for treating castrate resistant mPCa (mCRPC). After a median follow up of 34.5 months, the median PFS was 17 months, while the median OS was 43 months. Median survival post mCRPC was 17 months. Conclusion: Omani patients with mPCa present with high PSA and Gleason score and with widespread metastatic disease burden. Treatments offered are according to internationally accepted standards and have comparable PFS and OS as reported elsewhere.